Sanofi has entered into a licensing agreement with Adel, a clinical-stage biotech based in Seoul, South Korea, for the development and commercialization of an antibody therapy targeting Alzheimer’s disease. The total deal value could potentially reach over $1 billion.

Under the announced terms, Sanofi will provide an upfront cash payment of $80 million to Adel. The total transaction value may reach up to $1.04 billion, plus future royalties on sales.

In exchange, Sanofi secures exclusive global rights to Adel’s antibody therapy coded ADEL-Y01, along with access to related backup compounds. The partners view ADEL-Y01 as holding “first-in-class” potential for Alzheimer’s treatment.

About the ADEL-Y01 Therapy:

• It is a humanized monoclonal antibody designed to selectively target tau protein acetylated at lysine-280 (acK280).

• The tau protein is a critical factor in Alzheimer’s and other neurodegenerative conditions.

• The antibody is engineered to halt the aggregation and spread of toxic tau while preserving the function of normal microtubule-associated tau.

• ADEL-Y01 is currently being assessed in an ongoing global Phase 1 trial.

This agreement marks Sanofi’s second reported deal of the day, following the announcement of an expanded partnership with Dren Bio for an autoimmune disease therapy.

However, the same day also brought setbacks for Sanofi’s other pipeline assets: its investigational BTK inhibitor, tolebrutinib, for multiple sclerosis, faced an FDA delay in its decision timeline and missed the primary endpoint in a separate Phase 3 study for primary progressive MS (PPMS).

Source: https://www.fiercebiotech.com/biotech/sanofi-signs-1b-biobucks-pact-alzheimers-asset-2nd-biotech-deal-day

Alphyn Biologics, a US-based biotechnology company, has successfully completed a Series B funding round, raising $25 million. The round was twice-oversubscribed and spearheaded by QCA Investment Group, with participation from both existing and new investors.

The proceeds from the financing are designated to support several key objectives:

1. Supporting the global Phase IIb clinical trial for the company’s lead candidate, Zabalafin Hydrogel, targeting atopic dermatitis (AD).

2. Initiating a second Phase II clinical program for the molluscum contagiosum virus (MCV).

3. Expanding the supply of drug raw materials.

Zabalafin Hydrogel is being developed as a treatment that targets the interconnected drivers of AD, which include itch, inflammation, dry skin, and bacterial involvement. For AD, the hydrogel is specifically designed to treat the immuno-inflammatory component, pruritus, bacterial involvement, and xerosis.

The drug is also being investigated for its potential to address the virus, inflammation, itch, dermatitis, and bacterial infection associated with MCV. Alphyn suggests that, for MCV, the hydrogel could become the first direct antiviral drug that is both effective and safe, offering a new treatment option, particularly for pediatric patients.

The CEO of Alphyn Biologics thanked investors, stating that the financing reflects confidence in the company’s multi-target therapeutic drug platform. The company, which became operational in 2020, has now secured a total of $34 millionand is positioned to rapidly advance Zabalafin Hydrogel toward two pivotal Phase III trials.

Source: https://www.worldpharmaceuticals.net/news/alphyn-secures-25m-in-series-b-for-trial-of-zabalafin-hydrogel/

Swedish Orphan Biovitrum (SOBI) has reached an agreement to acquire Arthrosi Therapeutics Inc., a late-stage biotechnology company developing a highly potent and selective next-generation URAT1 inhibitor. This drug is intended to reduce serum urate (sUA) levels, mitigate flares, and dissolve tophi in patients with gout and tophaceous gout.

The total transaction value is estimated to be up to $1.5 billion, which comprises an upfront payment of $950 millionupon closing (subject to customary adjustments) and contingent consideration of up to $550 million. The acquisition is anticipated to close in the first half of 2026.

The acquisition strengthens SOBI’s gout treatment franchise by integrating pozdeutinurad (AR882). This investigational, once-daily oral URAT1 inhibitor is currently being evaluated in two fully enrolled global Phase 3 clinical studies for the potential management of progressive and tophaceous gout, with data expected to read out in 2026.

Pozdeutinurad has the potential to become the preferred therapy for patients with progressive gout whose persistent symptoms remain unresolved by first-line treatment. SOBI leadership believes the product has the capacity to materially accelerate the company’s growth through the mid-2030s and beyond.

Arthrosi Therapeutics expressed enthusiasm about joining forces with SOBI, trusting that SOBI’s global commercialization expertise will expedite their shared mission of delivering pozdeutinurad’s potentially transformative benefits to individuals living with gout.

Source: https://www.contractpharma.com/breaking-news/sobi-agrees-to-acquire-arthrosi-therapeutics/

The U.S. Food and Drug Administration (FDA) has granted an expanded approval for a targeted combination therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC) who harbor a BRCA2 gene mutation. This marks the first precision medicine approved specifically for this subset of patients.

The combination therapy is a dual-action tablet consisting of a PARP (poly-ADP ribose polymerase) inhibitor and an androgen-directed prostate cancer medication, used in conjunction with the corticosteroid prednisone to delay the progression of this aggressive form of prostate cancer.

The Phase 3 Amplitude study demonstrated that combining a PARP inhibitor with an androgen receptor pathway inhibitor could delay both radiographic and symptomatic disease progression in this patient population.

In the Amplitude trial, the new combination regimen, when added to androgen deprivation therapy (ADT), cut the risk of radiographic progression or death by 54% compared to the current standard of care (androgen-directed drug plus prednisone and ADT). The combination also extended the time to symptomatic progression by 59%.

Approximately 25% of mCSPC patients exhibit homologous recombination repair (HRR) gene alterations, including BRCA, which are linked to faster disease progression and poorer survival outcomes. While advances have been made in prostate cancer treatment, the company notes that nearly all patients eventually develop resistance to existing therapies, progressing to an incurable stage.

Exploratory analysis from the study indicated that the progression-free survival (PFS) benefit of the combination was notably larger in the BRCA-mutated subgroup, particularly in those with BRCA2 alterations. This narrowed approval mirrors the therapy’s initial nod in 2023 for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC)—a later disease stage.

The successful move into the earlier, castration-sensitive (mCSPC) treatment stage is a unique achievement among PARP inhibitors, strengthening the therapy’s position in the prostate cancer landscape.

Source: https://www.fiercepharma.com/pharma/jj-positions-its-parp-combo-akeega-new-prostate-cancer-subset-second-fda-nod

The U.S. Food and Drug Administration (FDA) has “proactively” awarded Johnson & Johnson (J&J) a Commissioner’s National Priority Voucher (CNPV) for a multiple myeloma combination therapy. This voucher speeds up the review process, targeting a decision one to two months following application submission, instead of the standard timeframe of up to 10 months.

The announcement follows the presentation of Phase 3 clinical trial results (MajesTEC-3) for the combination at the American Society of Hematology annual meeting. J&J, which had described the results as “unprecedented,” had already submitted an application for the two-drug combination intended for multiple myeloma patients who had received one to three prior lines of therapy.

FDA Commissioner, Dr. Martin Makary, stated that the FDA leadership read the study shortly after the results were published and proactively contacted the company about the CNPV because “When a treatment demonstrates outstanding trial results, we have a duty to patients to move swiftly.”

The MajesTEC-3 trial showed that the new combination regimen reduced the risk of death by 54% compared to traditional regimens. The progression-free survival (PFS) advantage of the new cocktail reached an impressive 83%. The overall survival (OS) curve for the combination suggests its potential as a functional cure for patients.

Analysts called the MajesTEC-3 results “exceptional.” However, a perceived weak point in the data was the exclusion of patients who were refractory to Darzalex, a drug that has become a standard first-line therapy. Analysts expressed concern that only 5% of the MajesTEC-3 patients had previously received Darzalex, potentially impacting the generalizability of the treatment’s efficacy to the refractory group.

The CNPV granted to J&J’s regimen is the 16th since the pilot program’s inception. The program prioritizes drugs aligning with U.S. national priorities, such as delivering innovative cures and supporting domestic drug manufacturing. Despite the priority status, questions have been raised regarding the legality of the initiative and the rigor of the FDA’s evaluation process for these drugs.

Source: https://www.fiercepharma.com/pharma/fda-proactively-awards-jj-national-priority-voucher-multiple-myeloma-drug-combo

The U.S. Food and Drug Administration (FDA) recently granted approval for a new combination regimen for patients with unresectable or metastatic HER2-positive breast cancer.

This authorization permits the use of a proprietary antibody-drug conjugate (ADC) therapy in combination with a targeted monoclonal antibody as a first-line treatment. The ADC therapy had previously secured approval in the third-line setting in 2019, which was later upgraded to the second-line setting in 2022. The monoclonal antibody component has been available since 2012, typically administered with another antibody and chemotherapy (the THP regimen), which has historically been the standard of care.

The approval is supported by interim data from the Phase 3 clinical trial (Destiny-Breast09). The findings indicated that the new combination therapy reduced the patients’ risk of disease progression or death by 44% compared to the THP regimen. The median progression-free survival (PFS) for the new combination was 40.7 months, significantly higher than the 26.9 months observed with the standard regimen. Medical experts suggest this new regimen is poised to become the new first-line standard of care for this patient population.

Regarding safety, the combination’s safety profile was consistent with the known profiles of its individual components. However, the ADC is associated with an increased risk of interstitial lung disease (ILD), which was noted in the trial. Adjudicated drug-related ILD or pneumonitis occurred in 12% of patients in the combination group, versus 1% in the THP group. While most cases were mild to moderate, two deaths (0.5%) were recorded in the combination arm. Clinicians are reportedly adept at managing this known side effect.

This ADC regimen is demonstrating substantial commercial promise, with combined sales reaching $3.75 billion in 2024, an increase from $2.57 billion in the previous year.

Source: https://www.fiercepharma.com/pharma/astrazeneca-daiichi-sankyo-score-fda-nod-enhertu-combo-breast-cancer

Occupational health specialist Concentra (NYSE:CON), a publicly traded company, has expanded its national footprint by establishing a new medical center in Hialeah, Florida. The facility, situated at 855 East 8th Avenue, is intended to improve local access to a range of employer-focused medical services and address rising regional demand.

The new location will deliver comprehensive services, including treatment for workplace injuries, physical rehabilitation, required medical assessments for commercial drivers (DOT examinations), pre-employment physicals, and substance abuse screenings. It will also integrate telemedicine capabilities through the company’s digital platform for managing minor work-related injuries. Concentra’s leadership indicated this strategic move aims to optimize service capacity for employers in the Hialeah area.

This addition expands the provider’s extensive network, which already comprises more than 625 centers nationwide. As of the end of the third quarter, the company maintained an operational network of 628 medical facilities and 409 clinics located directly at employer sites across 47 U.S. states. The organization, which reports serving approximately 50,000 patients daily and employing about 13,000 staff members, asserts that it is the nation’s largest occupational health provider based on facility count.

The $2.55 billion market cap company has shown strong financial performance, reporting a total revenue of $2.09 billion over the last twelve months, representing an 11.38% growth rate. Recent third-quarter results highlighted this upward trend with a 17% rise in revenue to $572.8 million and an 8.9% increase in net profit to $49.8 million. The company has also recently received a “Weight Increase” rating from JPMorgan, reflecting confidence in its growth trajectory and operational efficiency, including a flexible cost structure. Furthermore, Concentra has appointed a new Director of Data, Analysis, and Artificial Intelligence, signaling a focus on data strategy to support continued expansion.

Source: https://vn.investing.com/news/company-news/concentra-khai-truong-trung-tam-y-te-nghe-nghiep-moi-tai-hialeah-florida-249482